Jarislowsky Fraser Ltd lowered its position in GlaxoSmithKline PLC (NYSE:GSK) by 3.7% during the second quarter, Holdings Channel reports. The institutional investor owned 843,578 shares of the pharmaceutical company’s stock after selling 32,537 shares during the period. Jarislowsky Fraser Ltd’s holdings in GlaxoSmithKline PLC were worth $36,375,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Lincluden Management Ltd. raised its position in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC raised its position in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares in the last quarter. Roundview Capital LLC raised its position in shares of GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares in the last quarter. Dodge & Cox acquired a new position in shares of GlaxoSmithKline PLC during the fourth quarter worth $1,416,000. Finally, Wesbanco Bank Inc. raised its position in shares of GlaxoSmithKline PLC by 2.8% in the first quarter. Wesbanco Bank Inc. now owns 12,765 shares of the pharmaceutical company’s stock worth $538,000 after buying an additional 350 shares in the last quarter. Hedge funds and other institutional investors own 8.96% of the company’s stock.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 1.176% on Thursday, hitting $42.919. 811,065 shares of the stock traded hands. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $45.58. The firm has a 50 day moving average price of $43.32 and a 200 day moving average price of $41.69. The firm has a market cap of $104.85 billion, a PE ratio of 48.772 and a beta of 1.04.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.62. The company had revenue of $9.23 billion for the quarter, compared to analyst estimates of $9.09 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. On average, equities analysts forecast that GlaxoSmithKline PLC will post $2.86 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, July 13th. Stockholders of record on Friday, May 12th were given a dividend of $0.483 per share. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date was Wednesday, May 10th. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.55%. GlaxoSmithKline PLC’s dividend payout ratio is presently 233.74%.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/07/20/jarislowsky-fraser-ltd-reduces-stake-in-glaxosmithkline-plc-nysegsk.html.

A number of equities analysts have weighed in on GSK shares. Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 13th. BNP Paribas lowered their price target on shares of GlaxoSmithKline PLC to $37.00 in a report on Thursday, April 6th. Berenberg Bank raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Finally, TheStreet raised shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a report on Friday, May 19th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the company. GlaxoSmithKline PLC currently has a consensus rating of “Buy” and an average price target of $46.00.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.